GraftAssure Lowering Allograft rejeCTIon by Combination- (GALACTIC) Trial
Part of paid clinical trials in Livingston, New Jersey.
- Sponsor
- Insight Molecular Diagnostics
- Study ID
- NCT07551531
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Kidney Transplant
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Study Details
The GALACTIC Registry study purpose is to validate the Combination Model-score (CM-score) for increased accuracy in the percentage of the positive predictive value (PPV) of allograft rejection results for the GraftAssure (GraftAssureCore and GraftAssureDx) assay. This will also be correlated with the biopsy yield and treatment decisions. The GraftAssure assay is a diagnostic test intended for the quantitative measurement of dd-cfDNA in plasma from kidney transplant recipients. The test is minimally invasive, and is intended to be used in conjunction with standard clinical assessment and other laboratory findings as an aid in the detection of allograft rejection.
Key Dates
- First listed
- Apr 27, 2026
- Start date
- Jun 30, 2026
- Status verified
- Jul 2026
- Primary completion
- Dec 31, 2032
- Completion
- Jun 30, 2033
Study Design
- Enrollment
- 5,000 participants (estimated)
Arms
- Arm: Kidney transplant recipientsAdult kidney transplant recipients at least 2 weeks post-kidney transplant
Primary Outcome Measure
Detect Rejection [ Time Frame: 7 years ]
Central Contacts
- Annum Zhara, MSc.1-949-554-4946
- Haley Russell
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Cooperman Barnabas Medical Center | Livingston | New Jersey | 07039 | Anup Patel, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Livingston, NJ
Related Studies
- Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney TransplantationPHASE3 · Recruiting · Alexion Pharmaceuticals, Inc. · Phoenix, Arizona
- Study of Combined Kidney and Blood Stem Cell Transplant From a Brother or Sister DonorPHASE1/PHASE2 · Recruiting · Jeffrey Veale, MD · Los Angeles, California
- The KidneyCARE (Community Access to Research Equity) StudyRecruiting · Tufts Medical Center · Danville, Pennsylvania
- Assessment of Biomarker-Guided CNI Substitution In Kidney TransplantationPHASE2 · Recruiting · National Institute of Allergy and Infectious Diseases (NIAID) · Birmingham, Alabama